Burden of gallbladder cancer in Central and South America  by Izarzugaza, M.Isabel et al.
Cancer Epidemiology 44S (2016) S82–S89Burden of gallbladder cancer in Central and South America$
M.Isabel Izarzugazaa, Leticia Fernándezb, David Formanc, Mónica S. Sierrac,*
a Euskadi Cancer Registry, Vitoria-Gasteiz, Spain
bNational School of Public Health of Cuba, Biostatistics Department, Cuba
c The International Agency for Research on Cancer, Cancer Surveillance Section, Lyon, France
A R T I C L E I N F O
Article history:
Received 16 November 2015
Received in revised form 26 July 2016
Accepted 31 July 2016
A B S T R A C T
Rationale and objective: Gallbladder carcinoma (GBC) is a rare neoplasm yet it is the most common
malignancy of the biliary tract and its prognosis is poor. Incidence of GBC is high in some areas of Central
and South America and the Caribbean. We described the current burden of GBC in Central and South
America (CSA).
Methods: We obtained GBC incidence data from 48 population-based cancer registries in 13 countries in
CSA, and national level cancer death data from the WHO mortality data base for 18 countries. We
estimated World population age-standardized incidence and mortality rates per 100,000 persons-years,
including distribution and incidence rates by anatomic subsite.
Results: GBC rates were the highest in countries located in the Andean region. In 2003–2007, Chile had the
highest incidence and mortality rates in CSA (17.1 and 12.9 in females and 7.3 and 6.0 in males,
respectively). Females had higher GBC rates than males. The most frequently diagnosed anatomic subsite
was gallbladder (60%). Unspeciﬁed subsite represented 21% of all cases. Trends in incidence and mortality
of GBC remained unchanged in Argentina, Brazil, Chile and Costa Rica in 1998–2008.
Conclusion: GBC rates varied extensively across the CSA region reﬂecting, in part, differences in data
quality, coverage and healthcare access. Chile had the highest GBC rates in CSA and the world. The large
proportion of unspeciﬁed cases indicates low precision in diagnosis/registration and highlights the need
to promote and improve cancer registration in the region to better understand the burden of GBC in CSA.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Gallbladder carcinoma (GBC) is a relative rare neoplasm yet it is
the most common malignancy of the biliary tract [1,2]. These
epithelial tumors may arise either from the gallbladder, the
extrahepatic bile ducts, or the ampulla of Vater, altogether
anatomically known as the biliary tract [3]. GBC is multifactorial
disease resulting from a multistep process involving cumulative
genetic alterations which lead to neoplastic transformation [4];$ This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).history of gallstones, obesity, infections, and ethnicity have been
associated with an increased risk of GBC [5–9]. GBC prognosis is
poor, approximately 30% of patients with lesions conﬁned to the
gallbladder mucosa survive 5-years and 10% with more advanced
stages survive 1-year [2,10]. A small percentage of patients are
diagnosed at an early stage where complete surgical resection
provides a chance of cure [10].
Based on current estimates, more than 178,000 new GBC cases
and 143,000 GBD deaths occurred worldwide in 2012, representing
less than 1.5% of the total number of cases and 1.7% of the total
number of cancer-related deaths. In Central and South America
(CSA), approximately 15,000 new GBC cases and 13,000 cancer-
related deaths were estimated to occur in 2012 [11]. GBC incidence
and mortality rates exhibit striking geographic variation across the
globe, with rates reaching epidemic levels in some regions of CSA
[12], particularly in the Andean Area [13]. GBC rates also vary by
sex; female rates are 3–5 times higher than those in males [1,2,6,7].
GBC afﬂicts some speciﬁc ethnic groups and indigenous popula-
tions. In the United States GBC is more frequent among Hispanic
populations, with incidence rates twice as high than those of non-. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
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respectively), or Native American Indians (14.5 in female) [7,14]. In
South America, high mortality rates have been reported particu-
larly in Chilean Mapuche Indians, Bolivians, and Chilean Hispanics
(3.5–15.5 per 100,000) [2]. These remarkable variations may be
explained by differences in the prevalence of environmental
exposures, genetic predisposition to carcinogenesis, and tumor site
[2]. For instance, tumors originating in extra-hepatic bile duct site
are more frequent in Asia [3] than in America or Europe and affect
males more than females. Genetic alterations and molecular
changes reported in GBC are suggested that vary by subsite,
histological type and age of onset [15].
Incidence rates of GBC have been increasing over the last 3–
4 decades in some parts of Japan and China while in other regions
of the world rates have remained stable or declined [7,16,17]. Time
trend incidence data on GBC in CSA is limited, except in Cali,
Colombia where incidence of GBC has declined only in females
from 1992 to 2002 [7]. Mortality rates from GBC have been
decreasing in males from Colombia (1992–2002), Ecuador and
Mexico (1995–2007) but it has been increasing in Costa Rica
(1992–2002). In Chile mortality rates remained stable in both
females and males (1985–2002) [13,18,19]. There are no clear
reasons to explain the decrease in mortality, however better
diagnostic tools, increase and standardization of gallstones surgery
and changes in the international classiﬁcation of diseases are
thought to be responsible for the declines [18–21]. Recent
estimates indicate that the burden of GBC is expected to increase
in the CSA region by more than 80% by the year 2030 (27,000 new
cases and 24,000 deaths) due to demographic changes [11]. The
purpose of this study was to describe the current burden of GBC in
the CSA region, including information on incidence by anatomical
subsite. We also reviewed known risk factors for this malignancy to
further our understanding on the etiology of GBC in CSA in order to
guide future hypothesis testing studies on GBC in the region.
Finally, we discussed the need to improve and promote cancer
registration in CSA to better understand the burden of GBC and
facilitate future GBC control programs in CSA.
2. Methods
The present analysis includes gallbladder and other biliary
cancer (C23-C24), as coded using the International Classiﬁcation of
Diseases for Oncology (ICD-O). The data sources and methods are
described in detail in an earlier article in this issue. In brief, we
obtained regional and national-level incidence data from 48 popu-
lation-based cancer registries in 13 countries and nationwide
cancer deaths from the World Health Organization (WHO)
mortality database for 18 countries. To allow data comparisons
across countries, we used standard methods to check the incidence
data consistency and quality [22]. All incidence data were
converted to the latest version of ICD-O (ICD-O-3) [23]; the data
were subsequently translated to the 10th edition of the Interna-
tional Classiﬁcation of Diseases (ICD-10) [24]. Nationwide mortal-
ity data from WHO systematically undergo data veriﬁcation, andTable 1
Countries and cancer registries included in the analysis of time trends.
Country Name of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry the data are coded in ICD-10 to avoid misclassiﬁcation of cancer
mortality over time [25]. We estimated age-standardized inci-
dence (ASIR) and mortality (ASMR) rates per 100,000 person-years
using the direct method and the World standard population
[26,27]. We estimated national ASIRs by aggregating the data from
the available cancer registries using a weighted average of local
rates. Trends in incidence were estimated only for 4 countries that
provided written consent to use their data or submitted new data
for 10-years and we matched mortality data to the same time-
period (Table 1). To describe incidence and mortality time trends,
we calculated the estimated annual percent change (EAPC) for the
most recent 10-year period using the method proposed by Esteve
et al. [28]. All of the EAPCs were tested for equality to zero by using
the corresponding standard errors. We considered EAPCs statisti-
cally signiﬁcant if the p-value  0.05. We conducted the data
analysis in Stata version 12.1 (StataCorp) [29].
We also considered incidence information by anatomical
subsite as coded in ICD-O-3, the most speciﬁc classiﬁcation used
by cancer registries, in order to differentiate between gallbladder
site (C23), unspeciﬁed site (C24.9) and other parts of the biliary
tract (C24.0-C24.8).
3. Results
3.1. Age-standardized incidence and mortality rates
The results relate to the entire biliary tract (C23-C24),
altogether comprises 7961 GBC tumors for both sexes, collected
by the participating cancer registries in CSA. The incidence and
mortality rates of GBC vary extensively across countries within the
CSA region (Tables 2 and 3). Overall, females had consistently
higher GBC incidence and mortality rates than males (except in
French Guyana), with female-to-male ratios ranging from 1.2-
4:1and 1.1-11.4:1, respectively. In Central America, ASIRs the
highest incidence rates were in Costa Rica (2003–2007) (2.9 for
females and 1.8 for males). However, ASMRs were highest in
Mexico (2006–2010) (2.8 for females and 1.5 for males). In South
America, the highest GBC incidence and mortality rates were
observed in Chile (17.1 and 12.9 in females and 7.3 and 6.0 in males,
respectively).
Quality indicators of diagnosis and coverage are shown in
Tables 2,3. The percentage of microscopically veriﬁed (MV)
incident cases ranged from about 50% to 70% in most countries,
except in females in El Salvador, French Guyana, and Mexico (100%
MV) and males in Mexico (100% MV). The percentage of cases
identiﬁed by death certiﬁcation only (DCO) ranged from 0% to 36%.
3.2. Time trends
In the four countries we analyzed, Chile (1997–2008) consis-
tently had the highest incidence and mortality rates from GBC over
time than Argentina (1997–2006), Brazil (1997–2006) and Costa
Rica (1985–2007) for both females and males (Fig. 1). Among
females, trends in age-adjusted GBC incidence and mortality havePeriod % of the population covered
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
Table 2
Age-standardized incidence and mortality rates from gallbladder cancer (C23-C24) among males in Central and South American Countries.
Country by Subregion Period Incidence National Mortality
Cases Crude rate ASR (W) MV (%) DCO
(%)
Rankz Deaths Crude rate ASR (W) Rankz
CENTRAL AMERICA
Belize 2003–2007 . . . . . . 1 0.1 0.2 18
Costa Rica 2003–2007 160 1.5 1.8 58 14 20 101 0.9 1.1 16
Cubay 2004–2007 32 2.0 1.2 72 6 21 200 0.9 0.6 17
El Salvadory 1999–2003 41 0.3 0.4 46 0 10 104 0.7 1.0 15
Guatemala 2003–2007 . . . . . . 153 0.5 0.8 10
Mexicoy 2006–2010 139 0.8 1.0 100 0 19 2496 0.9 1.5 15
Nicaragua 2003–2007 . . . . . . 73 0.5 1.0 11
Panama 2003–2007 . . . . . . 54 0.7 0.8 15
SOUTH AMERICA
Argentinay 2003–2007 409 3.3 3.2 56 36 17 2303 2.4 2.0 15
Boliviay 2011 33 2.5 2.7 82 0 5 . . . .
Brazily 2003–2007 886 1.6 2.1 59 30 20 3985 0.9 1.0 15
Chiley 2003–2007 156 6.7 7.3 51 23 9 2498 6.2 6.0 5
Colombiay 2003–2007 189 2.1 2.4 60 13 19 1055 1.0 1.4 14
Ecuadory 2003–2007 147 3.1 3.9 54 20 12 303 0.9 1.2 10
French Guyanay 2003–2008 5 1.0 1.9 100 0 19 . . . .
Paraguay 2003–2007 . . . . . . 56 0.4 0.5 16
Peruy 2001–2005 26.3 2.9 3.1 58 27 14 620 0.9 1.3 9
Suriname 2003–2007 . . . . . . 2 0.2 0.2 18
Uruguay 2005–2007 195 4.1 2.8 57 24 18 163 3.4 2.3 16
Venezuela 2003–2007 . . . . . . 447 0.7 0.9 15
ASR (W), age-standardized (World population) rate per 100,000; MV, microscopic veriﬁcation; DCO, death certiﬁcation only.
y Incidence rates were estimated using aggregated data from regional cancer registries.
z Rank across cancer types, based on highest ASR excluding: All sites but C44 and All sites.
Table 3
Age-standardized incidence and mortality rates from gallbladder cancer (C23-C24) among females in Central and South American Countries.
Country by Subregion Period Incidence National Mortality
Cases Crude rate ASR (W) MV (%) DCO
(%)
Rankz Deaths Crude rate ASR (W) Rankz
Central America
Belize 2003–2007 . . . . . . 10 1.4 2.2 9
Costa Rica 2003–2007 289 2.8 2.9 65 15 14 190 1.8 1.9 12
Cubay 2004–2007 40 2.5 1.4 65 5 22 419 1.9 1.2 17
El Salvadory 1999–2003 195 1.4 1.6 64 1 7 288 1.9 2.1 7
Guatemala 2003–2007 . . . . . . 325 1.0 1.6 9
Mexicoy 2006–2010 316 1.8 2.0 100 0 13 5754 1.9 2.8 10
Nicaragua 2003–2007 . . . . . . 230 1.7 2.6 7
Panama 2003–2007 . . . . . . 112 1.4 1.4 12
South America
Argentinay 2003–2007 650 5.0 4.0 58 34 15 3924 4.0 2.7 9
Boliviay 2011 66 4.9 5.3 73 0 3 . . . .
Brazily 2003–2007 1670 2.7 2.8 63 27 18 8467 1.8 1.8 10
Chiley 2003–2007 422 19.0 17.1 55 15 2 6658 16.2 12.9 1
Colombiay 2003–2007 462 4.6 4.3 70 12 12 2502 2.3 2.7 10
Ecuadory 2003–2007 321 6.2 6.8 59 14 8 648 1.9 2.2 8
French Guyanay 2003–2008 3 0.6 1.1 67 0 21 . . . .
Paraguay 2003–2007 . . . . . . 136 0.9 1.3 9
Peruy 2001–2005 514 5.3 5.6 63 22 10 1373 2.0 2.5 7
Suriname 2003–2007 . . . . . . 7 0.6 0.6 12
Uruguay 2005–2007 358 7.0 3.7 52 29 15 281 5.4 2.7 10
Venezuela 2003–2007 . . . . . . 941 1.4 1.7 10
ASR (W), age-standardized (World population) rate per 100,000; MV, microscopic veriﬁcation; DCO, dead certiﬁcation only.
y Incidence rates were estimated using aggregated data from regional cancer registries.
z Rank across cancer types, based on highest ASR excluding: All sites but C44 and All sites.
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remained almost unchanged in Brazil. In Argentinean females, GBC
incidence has been declining while mortality remained almost
unchanged. In Costa Rican females, GBC incidence rates began to
decline after 1995; while mortality rates sharply decreased
between 1997 and 2000 and seem to stabilize thereafter. However,
analysis of trends for the most recent 10-year period did not reveal
any statistically signiﬁcant change in either incidence or mortalityfrom GBC in these countries (Fig. 2). A similar pattern was observed
among males, although with rates being lower than in females
(Figs. 1, 2).
3.3. Distribution of gallbladder cancer by anatomical subsite
Almost 60% of all GBC diagnosed in the CSA region were
classiﬁed as malignant tumors of the gallbladder (C23), 22% were
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Fig. 1. Trends in gallbladder cancer (C23-C24) incidence and mortality, all ages.
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unspeciﬁed (C24.9). Argentina, Cuba and El Salvador had the
highest frequency of unspeciﬁed tumors (ranging from >33 to 43%)
(Table 4). Overall, females were more frequently diagnosed with
cancer of the gallbladder than males; female-to-male ratios
ranging from 2 to 6:1 (except in French Guyana). In contrast,
males had the highest frequency (10.70%) of tumors classiﬁed as
other parts of the biliary tract (C24.0-24.8); female-to-male ratios
ranging from 0.05-1:1 (except in French Guyana).
Among females, incidence rates of GBC in Central America
ranged from 0.85 in Cuba to 1.9 in Costa Rica; whereas in South
America ranged from 0.22 in French Guyana to 14.96 in Chile.
Incidence of cancer of the gallbladder (C23) among males in
Central America were between 0.15 in El Salvador to 0.59 in Costa
Rica; while in South America were between 0.88 in Brazil and
5.14 in Chile. Incidence rates for other parts of the biliary tract
(C24.0-24.8) and unspeciﬁed (C24.9) anatomic subsites were very
low ( < 1.0) in most countries of the region, except for Ecuador,
Chile, Argentina, Uruguay (males) and Peru (females) where rates
were slightly higher (between 1.06 and <1.7).
4. Discussion
Although GBC in CSA is a relative rare cancer, it was the second
most frequently diagnosed malignancy and the ﬁrst leading cause
of death due to cancer among Chilean females (2003–2007) and
the second and ﬁfth most common cancer diagnosis in Bolivian
(2011) females and males, respectively. These results were
consistent with GLOBOCAN estimations of 2012 for most CSA
countries [11]. We also observed striking geographic variation in
incidence and mortality rates from GBC (16-fold and 22-fold infemales and 18-fold and 30-fold in males, respectively), with some
of the highest rates in countries located in the Andean region,
particularly Chile, Ecuador, Peru and Bolivia. Chile and Ecuador.
Chile had the highest mortality rates of GBC among females and
males in the CSA region (12.9 and 6.0, respectively) which were
also among the highest in the world [25]. It is possible that the
observed geographic variation in GBC rates reﬂect in part
difﬁculties or inconsistencies in diagnosis and death certiﬁcations
as well as inadequate healthcare access [30].
The geographic variations in incidence and mortality from GBC
may, in part, reﬂect different distribution of gallstones [7], the
major risk factor for developing GBC. In Chile, for example, an
autopsy study revealed that the prevalence of gallstone disease in
1970–1979 was 45% in women and 20% in men (20 years old) [31].
Approximately 2–3% of the Chilean patients with symptomatic
gallstone disease have GBC at the time of cholecystectomy [32].
Although the role of gallstones in the development of GBC remains
poorly understood, it has been hypothesized that chronic
inﬂammation, repeated trauma to the gallbladder mucosa induced
by the presence of gallstones which may or not be accompanied by
chronic salmonella typhi infection, could lead to dysplasia and
malignant changes in the gallbladder mucosa [5]. Since only a
small portion (1–3%) of patients with cholelithiasis (presence of
1 gallstones) develop GBC [33] and approximately 20% of GBC
patients do not have previous cholelithiasis [2], other genetic and/
or environmental factors could also explain these variations [2,4].
Bertran et al. [10] reported higher incidence rates among Mapuche
descendants (38.6 in females and 9.2 in males) and Hispanic/
European descendants (21.98 in females and 8.6 in males) in
Valdivia, Chile [10]. Lazcano-Ponce and Rios-Dalenz also reported
high incidence rates of GBC, although lower than our estimates,
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Fig. 2. Estimated annual percent change in age-standardized incidence and mortality rates (per 100,000) from gallbladder cancer (C23-C24).
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1992 [2], and among Mestizo (4.1) or Indian people (7.2) in La Paz-
Bolivia (1978–1980) [34]. Unfortunately, we could not stratify the
data by race/ethnic because it is not systematically collected in
most cancer registries in the CSA region.
Although the role of chronic infection with salmonella typhi on
GBC development remains to be elucidated [35], a collaborative
case-control study of GBC conducted in Bolivia (La Paz) and Mexico
(Mexico City) revealed that physician diagnosed typhoid fever
increased the risk of GBC (odds ratio, OR = 12.7 [95% conﬁdence
interval, 1.5, 598.0]). Strong positive associations were also
reported in a meta-analysis among chronic typhoid carries and
the risk of GBC [35]. Between 1976–1985, Chile had one of the
largest epidemics of typhoid fever; however after the 1990s rates
of typhoid ﬁber began to decline due to public health interventions
[36]. It is still unclear, however, how the typhoid fever epidemic
would have impacted the present GBC rates because only a small
percentage (2–5%) of people who have acute salmonella typhy
become chronic carries and because of the long latency period for
GBC development [37].
We observed that females were more frequently affected by
GBC than males in every country in the CSA region, except in
French Guyana. Similar sex differences have been reported across
the globe [7,19]. It has been suggested that reproductive and/or
hormonal factors may play a role in GBC development since
women are twice as likely to form gallstones as men [38]. Although
the mechanisms are not well understood, increased exposure to
endogenous estrogen and progesterone seems to promote the
formation of biliary stones [39]. High parity and the number of
pregnancies have also been linked with an increased risk ofgallstones as well as an increased risk of GBC in women [7]. In
Chile, the prevalence of gallbladder disease and cholecystectomy is
greater in women than in men [31,32].
We did not detect any statistically signiﬁcant change in GBC
incidence and mortality rates in Argentina, Brazil, Chile or Costa
Rica either in females or males in the most recent 10-year period,
probably because of the small number of cases. Randi et al. [7]
reported increases in incidence trends of GBC among women (35–
74 years) in Cali, Colombia, from 1967 to 1981 and then declines
until 1996 (EAPC: 31%), whereas in men (35–74 years) incidence
rates remained stable between 1967 and 1996. Stable incidence
rates have also been described in other parts of the world [7].
Declines in female mortality rates of GBC have been reported in
Mexico (1998–2004) and Venezuela (1970–2004) [30] while in
Colombia, Costa Rica and Ecuador mortality rates remained fairly
constant during 1992–2002 [18]. Likewise, increases in male
mortality rates have been reported in Mexico (1971–2004) and
Costa Rica (1992–2002); while in Ecuador (1992–2002), Colombia
(1992–2002) and Venezuela (1970–2004) rates have declined
[18,30]. Such discrepancies could be explained by the different
period evaluated and the methods used to estimate the annual
percent change. However, further monitoring of GBC incidence and
mortality rates is necessary in order to identify statistically
signiﬁcant changes over time. Moreover, changes (decline) in GBC
mortality may, partly, be explained by changes in diagnosis and
certiﬁcation of the disease, due to the introduction of more
sensitive diagnostic tools (i.e. ultrasound-computerized transaxial
tomography, retrograde cholangiography, ﬁne needle biopsy) [30].
Excess body weight has been associated with several cancers,
including GBC. Overweight/obesity has been strongly related to an
Table 4
Age-standardized incidence rates from gallbladder cancer (C23-C24) in Central and South America, by anatomical subsite.
Sex Gallbladder (C23) Other parts of the biliary track (C24.0-24.8) Unspeciﬁed (C24.9)
Country by Subregion (period) n (%) ASR n (%) ASR n (%) ASR
CENTRAL AMERICA
Costa Rica (2003–07) Males 52 (33) 0.59 74 (46) 0.84 34 (21) 0.38
Females 194 (67) 1.9 59 (20) 0.62 36 (13) 0.34
Cubay (2004–07) Males 10 (31) 0.33 9 (28) 0.38 13 (41) 0.47
Females 23 (58) 0.85 1 (3) 0.02 16 (40) 0.56
El Salvadory (1999–03) Males 16 (39) 0.15 9 (22) 0.09 16 (39) 0.17
Females 116 (60) 0.96 14 (7) 0.13 65 (33) 0.53
Mexicoy (2006–10) Males 63 (45) 0.48 42 (30) 0.3 34 (25) 0.25
Females 240 (76) 1.5 33 (10) 0.21 43 (14) 0.28
SOUTH AMERICA
Argentinay (2003–07) Males 189 (46) 1.5 45 (11) 0.35 175 (43) 1.3
Females 398 (61) 2.5 32 (5) 0.21 220 (34) 1.2
Boliviay (2011) Males 19 (58) 1.5 10 (30) 0.84 4 (12) 0.29
Females 54 (82) 4.3 8 (12) 0.69 4 (6) 0.32
Brazily (2003–07) Males 365 (41) 0.88 367 (41) 0.86 154 (17) 0.36
Females 1023 (61) 1.7 420 (25) 0.69 227 (14) 0.37
Chiley (2003–07) Males 109 (70) 5.1 24 (15) 1.1 23 (15) 1.1
Females 364 (86) 15 16 (4) 0.64 42 (10) 1.5
Colombiay (2003–07) Males 71 (38) 0.9 60 (32) 0.75 58 (31) 0.74
Females 292 (63) 2.8 82 (18) 0.76 88 (19) 0.75
Ecuadory (2003–07) Males 48 (33) 1.3 61 (42) 1.6 38 (26) 0.99
Females 199 (62) 4.4 78 (24) 1.6 44 (14) 0.91
French Guyanay (2003–07) Males 3 (60) 1.3 1 (20) 0.23 1 (20) 0.39
Females 1 (33) 0.22 2 (67) 0.87 0 (0) –
Peruy (2001–05) Males 107 (41) 1.3 76 (29) 0.95 80 (30) 0.91
Females 310 (60) 3.4 81 (16) 0.89 123 (24) 1.3
Uruguay (2005–07) Males 81 (42) 1.1 74 (38) 1.1 40 (21) 0.54
Females 219 (61) 2.4 68 (19) 0.68 71 (20) 0.63
ASR (W), age-standardized (World population) rate per 100,000.
y Incidence rates were estimated using aggregated data from regional cancer registries.
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cholesterol supersaturation [33,41]. Gallstone formation has also
been strongly related with dieting, particularly in low-energy diets
and bariatric surgery, and weight cycling [41]. Park et al. [42] found
that per every 5 kg/m2 increased in BMI the risk of developing GBC
increased by 9%. It has been estimated that 7% and 27% the GBC that
occurred in Brazilian and Chilean women and 3% and 7% of GBC
that occurred in Brazilian and Chilean men in 2008 were attributed
to excess body weight, assuming a causal association [43]. This is of
particular relevance in the CSA region given that the prevalence of
overweight/obesity has increased since the 1990s [44], especially
in women and people living in urban areas [45].
There is new evidence suggesting that exposure to other
environmental factors, such as the aﬂatoxins, may increase the risk
of GBC [46,47]. A recent pilot study conducted in Chile revealed
that those with gallbladder cancer had a higher risk of having
increased levels of aﬂatoxins in their blood than controls with
gallstones or than community controls (RR = 4.0 [1.0, 78.0], and 2.5
[1.0, 16.7], respectively) [9]. However, given that the etiology of
GBC is still not well understood, the contribution of factors such as
history of gallstones, obesity and infections [5–9] on GBC risk in
CSA is challenging. Thus the study of these factors on GBC risk will
help to better understand the mechanism of GBC development in
the region.
Most of the variation in GBC observed across the CSA region
appears to be related to differences in the distribution of the
gallbladder (C23) category as it was the most frequent anatomic
subsite diagnosed and it occurred more frequently in females than
in males. Other parts of the biliary track (C24.0-24.8) affected more
frequently males than females (except in French Guyana). Despite
the large percentage of unspeciﬁed cases (21%), our results seem
consistent with previous reports [34,48]. In a report from the
cancer registry of La Paz, Bolivia (1978–1980), Rios-Dalenz et al.
[34] described higher rates for the gallbladder category (ratesbetween 1.5-10.0) than for the cancer of the extra-hepatic bile
ducts (rates between 0.5-3.8) or unspeciﬁed categories (rates
between 0 and 1.2); with rates being consistently higher in females
than in males.
Currently, there are no routine tests used to screen for GBC.
Early symptoms of GBC are vague and often confused with other
gallbladder problems. Early diagnosis of GBC may occur inciden-
tally after a cholecystectomy for symptomatic cholelithiasis. In
most cases, GBC is diagnosed late after laparoscopic cholecystec-
tomy and pathological evaluation, when the tumor has invaded the
bile ducts or has metastasized. Tumors identiﬁed at early stage are
often curable with a proper resection [4]. In CSA there are not early
detection programs for GBC. In Chile, the country with the largest
burden of GBC in the CSA region, the government included
prophylactic cholecystectomy in individuals with gallstone disease
in the Explicit Health Guarantees since 2006 and offered
abdominal ultrasonography and cholecystectomy for symptomatic
individuals 35–49 years old who have or are suspected to have
gallstones [49]. After 2010, cholecystectomy was offered to the
target population with gallstones regardless of the presence of
symptoms [50]. It has been estimated that 300–900 GBC cases
could be prevented given the current number of cholecystectomies
performed annually (30,000) in Chile, but with no impact in GBC
mortality [32]. Although prophylactic cholecystectomy conducted
in patients with symptomatic gallstones may prevent GBC in
endemic areas, in asymptomatic individuals this strategy would
not be effective and would be expensive given the rarity of this
malignancy.
5. Strengths and limitations
We conducted one of the largest and most comprehensive
studies on GBC burden in CSA to date. However, data patterns must
be interpreted with caution because there is a lack of national
S88 M.I. Izarzugaza et al. / Cancer Epidemiology 44S (2016) S82–S89coverage of incident cases in CSA, except for the national registries
of Costa Rica and Uruguay. Thus, nationwide incidence rates are
represented by aggregated data from regional registries which do
not cover the entire country (except for Costa Rica and Uruguay).
Registrations may also differ in completeness and data quality
which could explain the observed variation in GBC rates across the
region. Such differences in data completeness and quality depend
on the maturity of the cancer registry which could explain why the
incidence of GBC observed in Bolivia, El Salvador, and Mexico were
low. Despite our data limitations, comparisons of the observed
patterns with GLOBOCAN estimations of 2012 suggest consistent
results for most CSA countries [11], except for El Salvador and
Mexico. In our data for El Salvador and Mexico, mortality rates
were much higher than incidence suggesting that incidence rates
maybe under estimated perhaps due to under-registration or
inconsistencies in diagnosis and death certiﬁcations.
It is important to note that crude incidence and crude mortality
rates, which do not take in to account the underlying age structure
of a population, may be higher or lower than the corresponding
age-standardized rate mainly because of the size of the speciﬁc
population at risk. For instance, GBC is relatively a rare cancers
among younger people but is more frequent in the older
populations. Older populations may have higher rates of GBC if
the number of older people is a larger portion of the population. To
be able to make fair comparisons of GBC rates between countries,
rates were age-standardized using the World population to
eliminate the confounding effect of age. In this sense, for each
population, the age-standardized rate represents the number of
events (incident cases or deaths) that would have been expected if
the populations being compared had the same age distribution.
Regarding data quality indicators, for most CSA countries, the
percentage of MV cases was below 75%, except for El Salvador
(females), Mexico (males and females), and French Guyana
(females) where 100% of the cases were MV. A very high proportion
of MV cases indicates over-reliance on the pathology laboratory as
a source of information, and therefore failure to ﬁnd cases
diagnosed by other means [51,52]. There was a large percentage of
cases identiﬁed by DCO in several countries which raises questions
about the validity of the data because the information on death
certiﬁcates suffers from lack of accuracy as compared to the
information obtained from clinical or pathology records [53].
Approximately 21% of the GBC incident cases diagnosed in CSA
were unspeciﬁed (C24.9), for which the anatomic subsite is not
known. Argentina, Cuba and El Salvador had the highest frequency
of unspeciﬁed tumors (ranging from >33 to 43%), indicating low
precision of diagnosis or registration [53]. Therefore, geographic
patterns of GBC by anatomic subsite should be interpreted with
caution. This also limited meaningful comparisons by anatomic
subsite with other geographic areas. Similarly, the percentage of
MV incident cases, as an indicator of the validity of the diagnostic
information, partially reﬂects the anatomic subsite distribution. A
previous evaluation of nationwide mortality data indicated that
the quality of death registration data in some CSA countries may be
considered of medium or low quality [54]; studies on the accuracy
of GBC death certiﬁcation in CSA are lacking. The suboptimal data
quality of GBC identiﬁed in this study could lead to potentially
inaccurate conclusions regarding the disease burden in the CSA
region. Our results highlight the need for high quality data and
increased coverage in order to provide vital guidance for future
cancer control activities.
6. Conclusion
Incidence and mortality rates from GBC showed a remarkable
geographic variation, including incidence variations by anatomic
subsite, and sex disparity, with Chile and Ecuador experiencingsome of the highest rates in the world. According to the anatomic
subsite, most tumors were classiﬁed as gallbladder and unspeci-
ﬁed. Trends in incidence and mortality rates from GBC in
Argentina, Brazil, Chile and Costa Rica remained almost unchanged
in 1997–2008. Geographic variations in GBC rates may reﬂect
differences in disease ascertainment and diagnosis, healthcare
access, and death certiﬁcation practice. The observed GBC
incidence patterns should be interpreted with caution given the
lack of national coverage of incident cases in most CSA countries
and the large proportion of unspeciﬁed cases. This study highlights
the need to improve the quality of diagnosis and/or registration of
incident cases in CSA as well as the need to promote cancer
registration in the region in order to increase coverage. Population-
based registries provide the best ﬁgures to better understand the
burden of this malignancy and facilitate future GBC control
programs. The accuracy of certiﬁcation of GBC deaths in the region
is yet to be evaluated.
Future studies on the etiology of GBC in CSA, particularly in
high-risk populations, are still needed to better understand the
mechanism of GBC development in the region. Chile has begun
new studies to identify risk factors speciﬁc to the Chilean
population in order to derive preventive strategies to reduce the
GBC burden [32]. There is also a need to develop new diagnostic
markers for early detection of GBC that are easy to implement at a
large and cost-effective preventive actions.
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